ImmunoGen Inc expected to post a loss of 30 cents a share - Earnings Preview

ImmunoGen

27/02/2023 19:18

* ImmunoGen Inc  IMGN.OQ   IMGN.O  is expected to show a
fall in
quarterly revenue when it reports  results on March 1. 
    * The Waltham Massachusetts-based  company is expected to
report 
a 37.6% decrease in revenue to $17.478 million from $27.99
million a year ago, according to the mean estimate from 12
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for ImmunoGen Inc is
for a
loss of 30 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for ImmunoGen
Inc is
$12​, above​ its last closing price of $3.73. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.26       -0.25      -0.31     Missed  -21.8
 Jun. 30 2022  -0.20       -0.21      -0.24     Missed  -13.2
 Mar. 31 2022  -0.21       -0.21      -0.10     Beat    52.6​
 Dec. 31 2021  -1.63       -1.71      -0.17     Beat    90
 ​​Sep.        -0.18       -0.18      -0.18     Met     2.4
 30 2021                                                
 Jun. 30 2021  -0.18       -0.18      -0.15     Beat    17.7​
 Mar. 31 2021  -0.19       -0.19      -0.17     Beat    9.3
 Dec. 31 2020  -0.06       -0.08      0.16      Beat    297.5
 This summary was machine generated February 27 at 19:18 GMT. 
All figures in US dollars  unless otherwise stated